HBK Investments L P lessened its position in shares of Insmed, Inc. (NASDAQ:INSM) by 49.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 46,275 shares of the biopharmaceutical company’s stock after selling 46,140 shares during the quarter. HBK Investments L P owned about 0.06% of Insmed worth $1,443,000 at the end of the most recent reporting period.
A number of other institutional investors also recently bought and sold shares of INSM. Janus Henderson Group PLC increased its holdings in Insmed by 140.2% in the 3rd quarter. Janus Henderson Group PLC now owns 3,960,748 shares of the biopharmaceutical company’s stock valued at $123,615,000 after purchasing an additional 2,312,045 shares during the last quarter. BlackRock Inc. increased its holdings in Insmed by 11.7% in the 4th quarter. BlackRock Inc. now owns 7,830,604 shares of the biopharmaceutical company’s stock valued at $244,159,000 after purchasing an additional 817,915 shares during the last quarter. Alyeska Investment Group L.P. acquired a new stake in Insmed in the 3rd quarter valued at approximately $9,210,000. Ameriprise Financial Inc. increased its holdings in Insmed by 308.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 298,513 shares of the biopharmaceutical company’s stock valued at $9,316,000 after purchasing an additional 225,394 shares during the last quarter. Finally, Sphera Funds Management LTD. acquired a new stake in Insmed in the 3rd quarter valued at approximately $4,213,000. Hedge funds and other institutional investors own 99.08% of the company’s stock.
Several research firms recently weighed in on INSM. BidaskClub downgraded shares of Insmed from a “hold” rating to a “sell” rating in a report on Tuesday. Morgan Stanley began coverage on shares of Insmed in a research note on Wednesday. They issued an “overweight” rating and a $39.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $35.00 price target on shares of Insmed in a research note on Thursday, January 4th. ValuEngine upgraded shares of Insmed from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Robert W. Baird restated a “positive” rating and issued a $42.00 price target (up previously from $32.00) on shares of Insmed in a research note on Thursday, January 4th. Two analysts have rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $36.90.
Insmed (NASDAQ:INSM) last released its quarterly earnings data on Friday, February 23rd. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.18). sell-side analysts forecast that Insmed, Inc. will post -3.64 EPS for the current year.
Insmed Company Profile
Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.